The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men
Open accessAbstract
AIMS: The influence of ageing on the pharmacokinetics of zolpidem, an extensively prescribed hypnotic medication, was evaluated in healthy human volunteers. METHODS: A series of 16 elderly (age: 61-85 years) and 24 young (age: 22-42 years) volunteers received single 5 mg oral doses of zolpidem tartrate. Serum zolpidem concentrations were determined by HPLC with fluorescence detection in samples drawn during 8 h after dosage. The effect of testosterone on zolpidem biotransformation was evaluated in vitro using human liver microsomes. Possible induction of CYP3A protein expression and function was studied in cultured human hepatocytes. RESULTS: Among men, apparent oral clearance of zolpidem was decreased in elderly compared to young subjects (3.8 vs 11.0 ml min-1 kg-1, P < 0.01), Cmax was increased (93 vs 40 ng ml-1, P < 0.01), and half-life increased (2.7 vs 1.5 h, P < 0.03). Among women, zolpidem oral clearance was decreased in the elderly (3.0 vs 5.8 ml min-1 kg-1, P < 0.02), Cmax increased (108 vs 60 ng ml-1, P < 0.001), with no difference in t1/2 (2.3 vs 2.4 h). Among male subjects, free serum testosterone concentrations were lower in the elderly (10.5 vs 19.0 pg ml-1, P < 0.01), and were significantly correlated with zolpidem clearance (r2 = 0.46, P < 0.001). Multiple regression analysis indicated a greater relative contribution of serum testosterone than age to the oral clearance of zolpidem among men. In human liver microsomes, co-incubation of zolpidem (10 micro m) with varying concentrations of testosterone produced activation of biotransformation of zolpidem to its principal hydroxylated metabolite. Maximum activation was achieved at equimolar concentrations of testosterone (10 micro m). However, testosterone did not induce immunoactive CYP3A4 expression or catalytic function in cultured human hepatocytes. CONCLUSIONS: The increased Cmax and lower oral clearance of zolpidem in the elderly are consistent with recommendations of lower clinical doses of zolpidem in the elderly. Our clinical and in vitro data both suggest that reduced free serum testosterone may have a modulatory role in age-dependent changes in zolpidem pharmacokinetics in men.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Reflecting these concerns, the US Food and Drug Administration (FDA) revised zolpidem dosing recommendations in 2013, halving the prescribed doses for women.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Triad of Sleep Apnea, Hypertension, and Chronic Kidney Disease: A Spectrum of Common Pathology
Aziz, F., & Chaudhary, K. R. (2016) · Cardiorenal Medicine · doi:10.1159/000450796 · Cited by 3,285
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Psychopharmacology: The Fourth Generation of Progress
Brophy, J. J. (1995) · JAMA · doi:10.1001/jama.1995.03530220079046 · Cited by 1,582
Gray, A., Feldman, H. A., McKinlay, J. B., & Longcope, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,104
Insomnia and Its Treatment: Prevalence and Correlates
Mellinger, G. D. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790260019002 · Cited by 1,071
Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA · doi:10.1001/jama.1989.03430230088031 · Cited by 536
Ferrini, R. L., & Barrett-Connor, E. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009519 · Cited by 473
Benzodiazepines and Zolpidem for Chronic Insomnia: A Meta-analysis of Treatment Efficacy
Nowell, P. D. (1997) · JAMA · doi:10.1001/jama.1997.03550240060035 · Cited by 451
Drug-Induced Cognitive Impairment in the Elderly
Moore, A. R., & O’Keeffe, S. T. (1999) · Drugs & Aging · doi:10.2165/00002512-199915010-00002 · Cited by 410
Monjan, Simonsick, & Wallace (1999) · SLEEP · Cited by 402
Benzodiazepine Use and the Risk of Motor Vehicle Crash in the Elderly
Hemmelgarn, B. R. (1997) · JAMA · doi:10.1001/jama.1997.03550010041037 · Cited by 397
Holm, K. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00014 · Cited by 317
Malcolm, R. J., & Gross, J. A. (1984) · Postgraduate Medicine · doi:10.1080/00325481.1984.11698665 · Cited by 290
Clinical Pharmacokinetics and Pharmacodynamics of Zolpidem
Salvà, P., & Costa, J. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199529030-00002 · Cited by 273
Zolpidem Use and Hip Fractures in Older People
Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2001.49280.x · Cited by 272
Behavioral Pharmacology of Zolpidem Relative to Benzodiazepines A Review
Rush, C. R. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(98)00102-6 · Cited by 260
Epidemiology of Medication-Related Falls and Fractures in the Elderly
Cumming, R. G. (1998) · Drugs & Aging · doi:10.2165/00002512-199812010-00005 · Cited by 253
Foley, D. J., Monjan, A. A., Simonsick, E. M., Wallace, R. B., & Blazer, D. G. (1999) · PubMed · Cited by 253
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S., Harrel, L., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., & Shader, R. I. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12284-2 · Cited by 225
Self-citationElucidation of Distinct Ligand Binding Sites for Cytochrome P450 3A4
Hosea, N. A., Miller, G. P., & Guengerich, F. P. (2000) · Biochemistry · doi:10.1021/bi992765t · Cited by 220
Lu, C., & Li, A. P. (2001) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(01)00162-4 · Cited by 205
The Epidemiology of Serious Adverse Drug Reactions Among the Elderly
Atkin, P. A., Veitch, P. C., Veitch, E. M., & OGLE, S. J. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00005 · Cited by 203
Hepatic Drug Metabolism and Aging
Durnas, C., Loi, C., & Cusack, B. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019050-00002 · Cited by 202
Venkatakrishnan, K., Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., & Greenblatt, D. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13680-x · Cited by 200
Self-citationClinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121030-00002 · Cited by 182
Self-citationClinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly
Greenblatt, D. J., Harmatz, J. S., & Shader, R. I. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00003 · Cited by 175
Self-citationLi, A. P., Reith, M. K., Rasmussen, A., Gorski, J. C., Hall, S. D., Xu, L., Kaminski, D. L., & Cheng, L. K. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00071-9 · Cited by 172
Perloff, M. D., Moltke, L. L., Court, M. H., Kotegawa, T., Shader, R. I., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35332-7 · Cited by 169
Self-citationKenworthy, K. E., Clarke, S. E., Andrews, J., & Houston, J. B. (2001) · PubMed · Cited by 160
Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs
Greenblatt, D. J., Divoll, M., Harmatz, J. S., MacLaughlin, D. S., & Shader, R. I. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.191 · Cited by 150
Self-citationThe safety and tolerability of zolpidem — an update
DARCOURT, G., Pringuey, D., Sallière, D., & Lavoisy, J. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300109 · Cited by 139
Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations
Moltke, L. L., Greenblatt, D. J., Granda, B. W., Duan, S. X., Grassi, J. M., Venkatakrishnan, K., Harmatz, J. S., & Shader, R. I. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00953.x · Cited by 133
Self-citationGreenblatt, D. J., Harmatz, J. S., Moltke, L. L., Wright, C. E., Durol, A. L. B., Harrel-Joseph, L. M., & Shader, R. I. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39253-5 · Cited by 123
Self-citationEpidemiology of Adverse Drug Reactions in the Elderly by Drug Class
Beyth, R. J., & Shorr, R. I. (1999) · Drugs & Aging · doi:10.2165/00002512-199914030-00005 · Cited by 122
Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism
enp, J. M., Hall, S. D., Ring, B. J., Strom, S. C., & Wrighton, S. A. (1998) · Pharmacogenetics · doi:10.1097/00008571-199804000-00007 · Cited by 118
Shou, M., Dai, R., Cui, D., Korzekwa, K. R., Baillie, T. A., & Rushmore, T. H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008799200 · Cited by 117
Oxidative metabolism of zolpidem by human liver cytochrome P450S.
Pichard‐Garcia, L., Gillet, G., Bonfils, C., Domergue, J., Thénot, J., & Maurel, P. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06824-2 · Cited by 108
Clinical Geriatric Psychopharmacology
Targum, S. D. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.2.248 · Cited by 95
Age-related decline of plasma bioavailable testosterone in adult men
NAHOUL, K., & Roger, M. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90287-3 · Cited by 92
Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding Domains
Schrag, M. L., & Wienkers, L. C. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2401 · Cited by 76
Minimal Rebound Insomnia After Treatment with 10-mg Zolpidem
Ware, J. C., Walsh, J. K., Scharf, M. B., Roehrs, T., Roth, T. G., & Vogel, G. W. (1997) · Clinical Neuropharmacology · doi:10.1097/00002826-199704000-00002 · Cited by 75
Effects of Endogenous Steroids on CYP3A4-Mediated Drug Metabolism by Human Liver Microsomes
Nakamura, H., Nakasa, H., Ishii, I., Ariyoshi, N., Igarashi, T., Ohmori, S., & Kitada, M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.534 · Cited by 70
Denti, L., Pasolini, G., Sanfelici, L., Benedetti, R., Cecchetti, A., Ceda, G. P., Ablondi, F., & Valenti, G. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb03028.x · Cited by 65
Triazolam Substrate Inhibition
Schrag, M. L., & Wienkers, L. C. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0667-6_56 · Cited by 61
EEG profile of intravenous zolpidem in healthy volunteers
Patat, A. A., Trocherie, S., Thébault, J. J., Rosenzweig, P., Dubruc, C., Bianchetti, G., Court, L. A., & Morselli, P. L. (1994) · Psychopharmacology · doi:10.1007/bf02245455 · Cited by 59
Imidazopyridines in sleep disorders : a novel experimental and therapeutic approach
Sauvanet, J.-P., Langer, S. Z., Morselli, P. L., & Synthelabo, L. D. E. D. R. (1988) · Raven Press eBooks · Cited by 58
Kinetic and dynamic components of increased benzodiazepine sensitivity in aging animals.
BARNHILL, J. G., Greenblatt, D. J., Miller, L. G., Gaver, A., Harmatz, J. S., & Shader, R. I. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13216-3 · Cited by 54
Self-citationLu, P., Lin, Y. J., Rodrigues, A. D., Rushmore, T. H., Baillie, T. A., & Shou, M. (2001) · PubMed · Cited by 48
Schrag, M. L., & Wienkers, L. C. (2001) · PubMed · Cited by 37
Durol, A. L. B., & Greenblatt, D. J. (1997) · Journal of Analytical Toxicology · doi:10.1093/jat/21.5.388 · Cited by 36
Self-citationEffect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men
Jűrgens, G., Lange, K. H. W., Reuther, L. Ø., Rasmussen, B. B., Brøsen, K., & Christensen, H. R. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121373 · Cited by 36
Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P‐glycoprotein
Moltke, L. L., Weemhoff, J. L., Perloff, M. D., Hesse, L. M., Harmatz, J. S., Roth‐Schechter, B. F., & Greenblatt, D. J. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.329 · Cited by 32
Self-citationEffects of Age on In Vitro Midazolam Biotransformation in Male CD-1 Mouse Liver Microsomes
Warrington, J. S., Poku, J. W., Moltke, L. L., Shader, R. I., Harmatz, J. S., & Greenblatt, D. J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35385-6 · Cited by 28
Self-citationOlubodun, J. O. B., Ochs, H. R., Trüten, V., Klein, A., Moltke, L. L., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002237988 · Cited by 24
Self-citationMoltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S., & Shader, R. I. (1998) · Pharmacy and Pharmacology Communications · doi:10.1111/j.2042-7158.1998.tb00727.x · Cited by 22
Self-citationOlubodun, J. O. B., Ochs, H. R., Trüten, V., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002401382623 · Cited by 18
Self-citationPsychotropic drugs and the aging patient.
Pollock, B. G. (1998) · PubMed · Cited by 17
Cognitive toxicity of drugs used in the elderly
Moltke, L. L., Greenblatt, D. J., Romach, M. K., & Sellers, E. M. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.3/llvonmoltke · Cited by 15
Self-citation
Research works printed but not linked: 3
- Von Moltke LL, 1999, Pharmacokinetics of psychotropic drugs in the elderly, Annu Rev Gerontol Geriatr, 19, 53
- Mäenpää J, 1998, Human cytochrome P4503A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha–naphthoflavone, terfenadine and testosterone, Pharmacogenetics, 8, 137
- Ruegg CE, 1997, Cytochrome‐P450 induction and conjugated metabolism in primary human hepatocytes after cryopreservation, In Vitro Toxicol, 10, 217
Cited by
Sorted by citations
Harrison, T., & Keating, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 303
Rich-Edwards, J. W., Kaiser, U. B., Chen, G. L., Manson, J. E., & Goldstein, J. M. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00246 · Cited by 273
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 291
Self-citationGreenblatt, D. J., & Roth, T. G. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 284
Self-citationPrediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
Howgate, E. M., Rowland Yeo, K., Proctor, N. J., Tucker, G. T., & Rostami-Hodjegan, A. (2006) · Xenobiotica · doi:10.1080/00498250600683197 · Cited by 223
Metadata
- Authors
- Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J.
- Affiliations
- Tufts University (US)
- Corresponding author
- Greenblatt, David J.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-07-22
- Volume
- 56
- Issue
- 3
- Pages
- 297-304
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC1884349
- OpenAlex
- W2169843481
- Cited by
- 104
- References
- 60
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 8 · 2020: 2 · 2019: 9 · 2018: 1 · 2017: 3 · 2016: 8 · 2015: 4 · 2014: 12 · 2013: 6 · 2012: 4
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG-17880, R01AG017880)
- National Institute of Mental Health (MH 02137, MH 58435, R01MH058435)
- National Institute on Drug Abuse (R21DA013209, R01DA005258, DA 13209, DA05258)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK/AI 58496, R01DK058496)
- National Center for Research Resources (RR00054, M01RR000054)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- zolpidem, pharmacokinetics, aging, older adults, testosterone, CYP3A4, drug metabolism, oral clearance, Cmax, half-life, hypnotics, liver microsomes, CYP3A4 induction, sex differences, drug interactions, drug safety in older adults
- MeSH terms
- Zolpidem, Administration, Oral, Adult, Aged, Aged, 80 and over, Aging, Chromatography, High Pressure Liquid, Drug Interactions, Female, Half-Life, Humans, Hypnotics and Sedatives, Male, Microsomes, Liver, Middle Aged, Pyridines, Testosterone, GABA Agonists, Hepatocytes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
